Keywords:
Chemotherapy; craniospinal irradiation; group 3; immune microenvironment; immunocharacterization; medulloblastoma; microglia
Abstract:
Medulloblastoma is the most common childhood brain cancer. Mainstay treatments of radiation and chemotherapy have not changed in decades and new treatment approaches are crucial for the improvement of clinical outcomes. To date, immunotherapies for medulloblastoma have been unsuccessful, and studies investigating the immune microenvironment of the disease and the impact of current therapies are limited.